Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 28th Preview)
-
Pancreatic cancer—first-in-class RAS inhibition gets FDA approval
FDA cleared Revolution Medicines’ daraxonrasib (Rasonque), marking the first approved RAS inhibitor for advanced pancreatic ductal adenocarcinoma. The approval supports use in previously treated patients, following a practice-changing Phase 3 program. The pivotal trial data showed a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. Revolution’s once-daily oral regimen is designed to target a genetic driver in a disease that has historically seen limited benefit from traditional options. The decision also accelerates commercial expectations for the program and sets a regulatory benchmark for next-generation, mutation-targeted therapies in PDAC.
-
Dermatomyositis—Roivant’s brepocitinib becomes the first oral option
The FDA approved Roivant and Priovant’s brepocitinib for dermatomyositis, with the medicine marketed as Lisraya. It is the first major regulatory step for the oral drug and could expand Roivant’s autoimmune footprint. Dermatomyositis treatment has typically relied on high-dose steroids and other immune-suppressing therapies. Roivant said Lisraya is taken once daily, aiming to reduce the need for long-term steroid exposure. The approval also positions brepocitinib for broader payer and treatment-decision impact in a disease population with limited approved options.
-
Immunotherapy safety—first-dose tumor lysis syndrome reported with tarlatamab
A case report described a fatal tumor lysis syndrome episode after a single 1-mg starter dose of tarlatamab in a patient with relapsed small cell lung cancer. The complication emerged six days after dosing and occurred despite an initial limited clinical course. The report, published in Respirology Case Reports, highlights the need for heightened monitoring around early dosing when cytokine-release and rapid tumor shrinkage risks overlap. While tumor lysis syndrome remains rare, the timing in relation to the initial “priming” dose may prompt revisitation of precaution and risk-stratification practices for similar bispecific approaches.
-
Regulatory and diagnostics—Roche expands FDA-cleared HER2 companion testing for Ziihera access
Roche received an expanded FDA clearance for diagnostic tests tied to Jazz Pharmaceuticals’ Ziihera, extending HER2 status assessment into additional gastric and gastroesophageal cancer settings. The update supports patient selection for a broader use label. Roche said its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail can now be used for assessing HER2-positive status in metastatic gastroesophageal adenocarcinoma, including gastric, gastroesophageal junction, and esophageal cancers. For labs and oncologists, the decision reduces gaps in access to targeted treatment eligibility where earlier testing approvals did not cover esophageal cancer.
-
Deals—McKesson to buy Precision Medicine Group to strengthen oncology services
McKesson agreed to acquire Precision Medicine Group for about $2.25 billion in an all-cash transaction, aiming to deepen clinical research and biopharma commercialization capabilities. The deal combines Precision’s biomarker intelligence, lab services, and market access consulting with McKesson’s healthcare distribution and oncology assets. McKesson said Precision will be folded into its Oncology & Multispecialty segment after closing, pending regulatory approvals. The company framed the acquisition as an end-to-end bridge from clinical trial execution to patient delivery. The transaction underscores continued consolidation among service providers supporting biotech drug development lifecycles.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.